Award-Winning Molecular Diagnostics Technology
SALT LAKE CITY—October 29, 2015—Fluoresentric, Inc. today announced the licensing of its Xtreme Chain Reaction (XCRTM) chemistry to its subsidiary company, XCR Diagnostic’s (XCR Dx). XCR Dx will use this award-winning chemistry in its new Portable Diagnostic System (PDS) under development. XCR Dx’s PDS prototype development, based on its patent pending instrumentation technology, suggests this will be the first hand-held molecular diagnostic system to deliver sub 15-minute clinically actionable results at near patient, point of care.
Complete News Release upon request.
Watch extremely fast DNA amplification at the November AMP Annual Meeting in Austin, TX (booth #1824).
About XCR Diagnostics, Inc.
XCR Diagnostics Inc. (XCR Dx), a Fluoresentric Inc. company, is a start-up instrument provider advancing near patient hand-held molecular instrumentation, sample preparation and detection chemistry in regulated human diagnostic markets; domestically and internationally. The Company is positioned to deliver the first sub 15-minute diagnostic test system to the market in 2016. The combination of small portable platforms and revolutionary molecular reagents enables XCR Diagnostics to dramatically trim test times and reduce healthcare costs, with a vision to deliver hyper-accurate molecular diagnostics testing near patient at point of care.
About Fluoresentric, Inc.
Fluoresentric Inc., an Intellectual Property company, is positioned to monetize its XCR™ technology portfolio globally. With strong intellectual property initially in molecular amplification, the Company has expanded its intellectual property collection into instrumentation, sample prep and other application chemistries. Fluoresentric’s vision is to apply the Company’s intellectual property to an extensive set of commercial opportunities resulting in better and faster results processing for healthcare and other industries worldwide.
Help employers find you! Check out all the jobs and post your resume.
